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Summary Introduction
Mutation screening of the major autosomal dominant Autosomal dominant polycystic kidney disease
polycystic kidney disease gene (PKD1) has been compli- (ADPKD) is a common inherited disorder (incidence
cated by the large transcript size (ú14 kb) and by reitera- 1/1,000) and a frequent cause of end-stage renal disease
tion of the genomic area encoding 75% of the protein (ESRD). ADPKD is characterized by the progressive de-
on the same chromosome (the HG loci). The sequence velopment and enlargement of renal cysts, typically lead-
similarity between the PKD1 and HG regions has pre- ing to ESRD by late middle age (Gabow et al. 1992). A
cluded speciﬁc analysis of the duplicated region of PKD1, variety of extrarenal manifestations also are associated
and consequently all previously described mutations map with ADPKD, including hepatic cysts, cerebral aneu-
to the unique 3 region of PKD1. We have now developed rysms, and cardiac valve abnormalities, showing that
a novel anchored reverse-transcription–PCR (RT-PCR) this is a systemic disorder (Gabow 1990).
approach to speciﬁcally amplify duplicated regions of ADPKD is genetically heterogeneous, although the
PKD1, employing one primer situated within the single- majority (Ç85%) of cases are due to mutation of the
copy region and one within the reiterated area. This strat- polycystic kidney disease 1 gene (PKD1) (Peters and
egy has been incorporated in a mutation screen of 100 Sandkuijl 1992). Most of the remainder are due to muta-
patients for more than half of the PKD1 exons (exons 22– tion of the PKD2 gene, although a small number of
46; 37% of the coding region), including 11 (exons 22– families with disease unlinked to either of these loci have
32) within the duplicated gene region, by use of the pro- been described (Bogdanova et al. 1995; Daoust et al.
tein-truncation test (PTT). Sixty of these patients also were 1995; de Almeida et al. 1995). Comparisons of PKD1
screened for missense changes, by use of the nonisotopic and PKD2 families have shown that PKD1 is typically
RNase cleavage assay (NIRCA), in exons 23–36. Eleven a more severe disorder, with an average age at ESRD of
mutations have been identiﬁed, six within the duplicated Ç56 years, compared with Ç71.5 years for PKD2 (Ra-
region, and these consist of three stop mutations, three vine et al. 1992).
frameshifting deletions of a single nucleotide, two splicing The PKD1 gene has been identiﬁed (European Poly-
defects, and three possible missense changes. Each muta- cystic Kidney Disease Consortium 1994), and the geno-
tion was detected in just one family (although one has mic region (Burn et al. 1995) and cDNA have been
been described elsewhere); no mutation hot spot was iden- sequenced fully (Hughes et al. 1995; International Poly-
tiﬁed. The nature and distribution of mutations, plus the cystic Kidney Disease Consortium 1995). The gene cov-
lack of a clear phenotype/genotype correlation, suggest ers Ç52 kb of genomic DNA in 16p13.3 and is divided
that they may inactivate the molecule. RT-PCR/PTT into 46 exons. The transcript is 14,136 bp, and the
proved to be a rapid and efﬁcient method to detect PKD1 predicted protein, polycystin, consists of 4,302 amino
mutations (differentiating pathogenic changes from poly- acids. Polycystin is thought to be an integral membrane
morphisms), and we recommend this procedure as a ﬁrst- protein with a large extracellular region and multiple
pass mutation screen in this disorder. transmembrane domains (Hughes et al. 1995).
The PKD2 gene, situated in 4q21-23, recently has
been identiﬁed and characterized (Mochizuki et al.
1996). The transcript is Ç5.4 kb, and the 968-amino-Received December 20, 1996; accepted for publication March 13,
1997. acid product is predicted to be an integral membrane
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vated Ca2/ and Na/ channels, suggesting a related roleOxford, OX3 9DU, United Kingdom. E-mail address: peter@
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the structure of the genomic region encoding the gene. Pedigree 157 (P157).—The proband (OX1190) had a
positive family history, with elevated blood pressure andMost of the PKD1 gene lies in an area of DNA that is
reiterated several times elsewhere on the same chromo- chronic renal disease at age 33 years. His MZ twin
daughters were found to have a few cysts in each kidneysome (in 16p13.1). This duplicate area also encodes
three genes (the HG loci) that share substantial (Ç97%) at age 4 years, but the organs were not enlarged, and
the twins remained normotensive.homology with the ﬁrst 32 exons of PKD1 (European
Polycystic Kidney Disease Consortium 1994). The de- Pedigree 161 (P161).—OX1097 (ESRD onset at age
47 years) had an affected sister and three children, agesgree of homology between the PKD1 and HG regions
means that both generally are visualized simultaneously 28, 23 and 22 years, with renal cysts but normal renal
function.when analyzed by hybridization, PCR, or reverse-tran-
scription–PCR (RT-PCR) methods. Consequently, at Pedigree 130 (P130).—OX973 had a positive family
history, was hypertensive, and received a renal trans-present all of the 16 mutations characterized in PKD1,
except the translocation that helped in identiﬁcation of plant at age 52 years. His daughter was found to have
bilateral small cysts, on screening at age 7 years.the gene (European Polycystic Kidney Disease Consor-
tium 1994), are clustered in the 3 14 exons encoded by Pedigree 179 (P179).—OX46 was adopted and died,
at age 61 years, from a myocardial infarction, withsingle-copy DNA. These mutations include three intra-
genic deletions, four splicing defects, six nonsense muta- ESRD onset at age 52 years. He had an affected daugh-
ter, age 28 years, who had normal renal function.tions, an insertion of a nucleotide, and a possible mis-
sense mutation (European Polycystic Kidney Disease Pedigree 11 (P11).—P11 was a large family; ADPKD
could be traced through three generations, and the pro-Consortium 1994; Peral et al. 1995, 1996a, 1996b;
Turco et al. 1995; Neophytou et al. 1996; Rossetti et band (OX61; ESRD onset at age 51 years) had eight
children, ﬁve of whom were affected. The ﬁve affectedal. 1996). A second type of PKD1 mutation also has
been described: large deletions that disrupt PKD1 and children (ages 25–45 years) had renal function within
the normal range, but three were hypertensive.the adjacent tuberous sclerosis gene, TSC2 (Brook-Car-
ter et al. 1994). In these contiguous gene–syndrome Pedigree 229 (P229).—OX1056 (ESRD onset at age
63 years) had a negative family history and adoptedcases, a speciﬁc phenotype of tuberous sclerosis and se-
vere, childhood-onset polycystic kidney disease was ob- children.
Pedigree 109 (P109).—ADPKD could be tracedserved. These clearly are inactivating mutations of
PKD1 and indicate a central role for PKD1 in cases of through four generations, with ESRD onset at age 53
years in OX980. Her affected brother and father hadrenal cystic disease in tuberous sclerosis.
Previous studies have shown that the proportion of died at age 46 years and 42 years, respectively, and only
a niece with renal cysts was available for study.mutations detected in the single-copy region of PKD1
is consistent with mutations being spread evenly Pedigree 225 (P225).—ADPKD could be traced
through three generations, but OX18 (ESRD onset atthroughout the gene (Peral et al. 1996b) and, hence,
that the majority are located within the duplicated area. age 50 years), who is hypertensive, was the only surviv-
ing affected relative. His affected mother and grand-Consequently, we now have extended our mutation
screen to include the 25 most 3 exons of PKD1, 11 of mother had died at age 42 and 32 years, respectively.
Pedigree 3 (P3).—Three affected individuals werewhich lie in the duplicated area of the gene. We em-
ployed a novel approach to speciﬁcally amplify the du- available for study: OX21 (ESRD onset at age 42 years),
his sister (ESRD onset at age 42 years), and her daughter,plicated area of PKD1. In this screen of more than half
of the PKD1 exons, 10 novel mutations were character- who had normal renal function at age 25 years.
ized, including the ﬁrst changes detected within the du-
RT-PCRplicated area.
Total RNA was extracted from lymphoblast cell lines
by the method of Chomczynski and Sacchi (1987). FiveSubjects and Methods
micrograms of total RNA were employed in the ﬁrst-
Clinical Details strand cDNA synthesis in a total volume of 50 ml, ac-
cording to the method described elsewhere (EuropeanPedigree 187 (P187).—OX40 had a positive family
history but was the only living affected member of P187, Polycystic Kidney Disease Consortium 1994).
with ESRD onset at age 53 years. Her affected father,
Nonisotopic RNase Cleavage Assay (NIRCA)grandfather, cousin, and great uncle had died at age 48,
63, 43, and 60 years, respectively. NIRCA was adapted from methods described by
Myers et al. (1985) and Winter et al. (1985) (MismatchPedigree 193 (P193).—OX1055 (ESRD onset at age
57 years) had a negative family history and two daugh- Detect IITM; Ambion). The initial pairs of primers used
to amplify cDNA are listed in table 1. PCR ampliﬁcationters with negative renal ultrasounds at ages 37 and 34
years. was performed either as described by Harris et al. (1991)
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Table 1
Primers Used in Initial PCR
Mg2/ Annealing Position of Product
Sequence Concentration Temperature Producta Sizea
Name (5–3 ) (mM) (C) (nt) (bp) Exons
NIRCA:
7.8F TATGCCGCTCGTGCCTGAAGCAGAC
Mut 1 1.5 62 8247–10686 2,440 22–34
AH3 B2 TCCATGTGGGTGTCTTGGGTAGGG
AH3 F2 GCTTTGTGTTTCCTGAGCCGAC
Mut 2 and 3 1 60 9399–10686 1,288 26–34
AH3 B2 TCCATGTGGGTGTCTTGGGTAGGG
AH3 F9 TTTGACAAGCACATCTGGCTCTC
Mut 4 1 62 9983–11238 1,256 29–38
AH3 B7 TACACCAGGAGGCTCCGCAG
PTT:
7.8F TATGCCGCTCGTGCCTGAAGCAGAC
1 and 2 1.5 62 8247–10686 2,440 22–34
AH3 B2 TCCATGTGGGTGTCTTGGGTAGGG
Mut 4F GGACTCGTCCGTGCTGGAC
3 1.5 60 10324–12381 2,058 31–45
3A3 C2 ACGCTCCAGAGGGAGTCCAC
1 Long F CATGCTTTTTCTGCTGGTGACC
4 1 65 11239–13280 2,042 38–46
1 Long R TTAAAGTGCTGAAGCCCACAGAC
a In cDNA.
or by use of a dimethyl sulfoxide (DMSO)–containing AGGG-3, or the SP6 phage promoter (reverse),
5-TCATTTAGGTGACACTATAGGA-3. The PCRbuffer (Dode´ et al. 1990) and the conditions described
in table 1. When the size of the expected product was products were transcribed in vitro with the appropriate
T7 or SP6 polymerase to produce sense (S) and antisenseú1 kb, the PCR additive Taq ExtenderTM (1 unit/kb
ampliﬁed fragment; Stratagene) was added. To screen (AS) RNA probes, respectively. The S product from a
PKD1 sample was hybridized to an AS product of thefor mutations within the duplicated region, we used the
reverse primer AH3B2 (table 1 and ﬁg. 1), which is wild-type control, and vice versa, as was a control S
with a control AS. All the hybridized samples werelocated in the single-copy area (exon 34), to speciﬁcally
amplify PKD1. The speciﬁcity of products was tested treated with as many as three different RNases (I–III),
in separate reactions, and the cleaved products werewith the somatic-cell hybrids P-MWH2A (HG only) and
Hy145.19 (PKD1 only; European Polycystic Kidney Dis- analyzed on ethidium bromide–stained agarose gels
(2.5%–3%).ease Consortium 1994).
An aliquot of the initial product was used as a tem-
Protein-Truncation Test (PTT)plate for a nested reaction employing the primers and
conditions listed in table 2. These primers also contain, The initial PCR reaction employed the primers and
conditions shown in table 1. An aliquot of that productat their 5 ends, the sequence of either the T7 phage
promoter (forward), 5-GATAATACGACTCACTAT- was used as a template in the second, nested PCR
Figure 1 Map of the region of the PKD1 transcript analyzed (exons 22–46), showing the locations of described mutations. The exons
encoded by the duplicated area (hatched section), the single-copy region (blackened section), and the 3 UTR (unblackened/nonhatched section),
are illustrated. Each kilobase of the PKD1 transcript is numbered above the exons. The regions analyzed with each of the eight sets of primers—
four sets for NIRCA (Mut 1–Mut 4) and four sets for PTT (PTT 1–PTT 4)—are shown above the map. The primer AH3B2, used as an
anchored primer to obtain PKD1-speciﬁc products for analysis of the duplicated area, is shown above exon 34. Below the map the designation
of each mutation, the pedigree number (P), and the position of the change are shown. Arrows indicate stop or frameshifting mutations, and
asterisks denote missense changes.
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Table 2
Nested Primers
No. of
Mutations/
Mg2/ Annealing Position of No. of
Sequence Concentration Temperature Producta Product Sizea Samples
Name (5–3 ) (mM) (C) (nt) (bp) Exons Analyzed
Primers used in
NIRCA:
Mut 1 forward CCTCGATGGCATTCCAGACAC
1.5 65 8757–9525 769 (813)b 23–26 2/60
Mut 1 reverse CGGCTGGCATCCAACTGG
Mut 2 forward CATGTGCTGTGTGCCTGGTG
0.5 64 9450–9826 377 (421) 26–28 0/60
Mut 2 reverse CAGGTCCCTGACGATGACGTG
Mut 3 forward ATCGCCACCCCGCACAG
1 65 9719–10358 640 (684) 27–31 0/60
Mut 3 reverse ACGTGAGGAAGGAGCTGTCC
Mut 4 forward GGACTCGTCCGTGCTGGAC
0.5 65 10324–10941 618 (662) 31–36 2/60
Mut 4 reverse GCACCCACCCACCCTGAG
Primers used in
PTT:
PTT 1 forward TCGTGCCTGAAGCAGACGC
0.9 62 8255–9644 1,390 (1,429) 22–27 3/100
PTT 1 reverse CCCCATACAGCATGATGCCC
PTT 2 forward TTTGTGTTTCCTGAGCCGAC
1 60 9401–10686 1,286 (1,325) 26–34 1/100
PTT 2 reverse TCCATGTGGGTGTCTTGGGTAGGG
PTT 3 forward GAGGGAACGCTCAGTTGG
1 64 10451–12211 1,761 (1,800) 33–43 0/100
PTT 3 reverse CTTGACCAAAAGCAGGAAGAG
PTT 4 forward GCACTGGTACGCCTCGCC
1 65 12053–13222 1,170 (1,209) 43–46 3/100
PTT 4 reverse CGTGCAGCCATTCTGCCTG
a In cDNA.
b Plus extra primer sequence.
reaction, with the primers listed in table 2. The upstream PCR was performed, with use of the primers 7.8F/AH3
B2 (table 1), to generate a PKD1-speciﬁc product, fol-primer also had the T7 promoter sequence and transla-
tion-initiation codon, with Kozac consensus, engineered lowed by a nested reaction with primers entirely within
the duplicated region for OX46, OX1055, and5 to the gene-speciﬁc primer sequence: 5-GGATCC-
TAATACGACTCACTATAGGAACAGACCACC- OX1190. The nucleotide numbering and amino acid
numbering described by (Hughes et al. 1995) were usedATG-3 (Roest et al. 1993). A 250–500-ng portion of
each PCR product was transcribed and translated in a throughout the study.
TnT/T7-coupled reticulocyte lysate system (Promega),
Primer-Template Mismatches to Detect Mutationsaccording to the protocol recommended by the manu-
Primers to speciﬁcally amplify the mutant allele werefacturers, with the exception that the reactions were car-
designed to trace mutations that did not alter a restric-ried out in a 12.5-ml ﬁnal volume. Incorporation of 3H-
tion site in pedigrees P225 and P3. As well as a mutation-Leucine (TRK754; Amersham) in the in vitro translation
speciﬁc change to the 3-terminal nucleotide, an addi-reaction was used to detect the translated products after
tional mismatch was engineered within the last fourelectrophoretic separation (16–20 h at 10 W) on a 15%
bases, to ensure allele-speciﬁc ampliﬁcation (Kwok et al.or 17% SDS-polyacylamide gel. High-range 14C Rain-
1990). For the change 12739delA (P225), we used abow markers (Amersham) were used. The gel was ﬁxed
downstream primer with two mismatches from the nor-in a 25:65:10 mixture of isopropanol:water:acetic acid
mal sequence—18-reverse, 5-TCGGAGCCAGCG-for 30 min, soaked in AmplifyTM (Amersham) for 30
CTGGCG-3 (12756–12739)—and the normal up-min, and ﬁnally was dried and autoradiographed for
stream primer—18-forward, 5-TTGCGTGGAGAG-16–48 h at 070C.
CTGTACCG-3 (12545–12564). A 212-bp product
DNA Sequencing was obtained only from individuals with the mutation.
For the change R4227X (12890CrT) in P3 (the samePCR products were sequenced directly by including a
single 5 biotinylated primer as described elsewhere stop mutation as was seen in P89; Peral et al. 1996b),
we used the modiﬁed upstream primer 21-forward—5-(Peral et al. 1996b). For sequencing of mutations located
within the duplicated area, either a 5 biotinylated TGCTCACCCAGTTTGAGT-3 (12873–12890)—and
the downstream primer 21-reverse—5-CGTGCAGCC-primer, 5-GTGGGTGTCTTGGGTAGGG-3 (10681–
10662), fromwithin the single-copy area was employed, ATTCTGCCTG-3 (13222–13204)—giving a mutant-
speciﬁc 350-bp product.for patients OX1056, OX973, and OX61, or an initial
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Genomic Analysis in P11 mutations in exons 23–36, by NIRCA (for details of
primers employed, see tables 1 and 2). Ten of theseThe mutation 9299delC in P11 abolished a CvJi I re-
exons (23–32) lie within the duplicated area.striction site and was analyzed in genomic DNA from
Nonsense mutation in P187.—Analysis with the Mut11 family members, with an anchored PCR reaction.
4 primers showed abnormal fragments after digestionGenomic DNA (100 ng) was ampliﬁed initially with the
with RNase in individual OX40 (P187) (ﬁg. 2a). Directprimers 61-forward—5-AGTCACTCCAGGGTG-
sequencing revealed a substitution (10748CrT) in exonCTGACC-3—and AH3B2 (table 1). An aliquot of the
35, giving rise to the stop mutation Q3513X (ﬁg. 2c).5,696-bp product was used as template with the primers
This mutation abolished restriction sites for both PstI25-forward—5-GAGCAGAGACCCAGCGGG-3—
and AlwNI, and these were used to conﬁrm the changeand 25-reverse—5-AGGTGGCGGGTGAGGCAG-3.
in genomic DNA.The resulting 195-bp product was digested with CvJiI
Missense mutations within the duplicated area.—and was analyzed on a 4% agarose gel. Normal individ-
Assay of exons 23–26 (primers Mut 1; table 2) revealeduals had ﬁve fragments—61, 42, 36, 34, and 22 bp—
two samples with abnormal fragments: OX1055 (P193)but a restriction site was destroyed in mutation carriers,
(ﬁg. 2b) and OX1190 (P157). Direct sequencing ofproducing a novel fragment of 94 bp (61/34-1 bp).
OX1055 revealed the substitution—9189TrC, chang-
Analysis of the Intronic Deletion in P229 ing Leu (CTG) to Pro (CCG) (missense mutation
L2993P) in exon 25. This mutation created a FokI re-Somatic-cell hybrids separating both chromosomes 16
striction site that was used to conﬁrm the mutation infrom OX1056 were generated as described elsewhere
genomic DNA and to show that the two unaffected(Deisseroth and Hendrick 1979). To trace the intronic
daughters in this pedigree did not inherited this change.deletion in P229, 50 ng of genomic DNA from three
Direct sequencing of OX1190 revealed the mutationfamily members and the hybrids (BB4 and BB2-5) was
9258ArG, changing Gln to Arg (missense mutationampliﬁed with the primers Mut 4F (table 2) and AH3B2
Q3016R). This change creates a restriction site forMspI,(table 1). An aliquot of the 753-bp product was ampli-
which was employed to conﬁrm the mutation in theﬁed with the primers Mut4F and the reverse primer 5-
affected MZ twin daughters in this pedigree. GenomicGGAACCCACCTCTTAGAATCATCC-3, and the
DNA of additional unrelated patients was screened for203-bp product was analyzed in a 3% agarose gel.
the changes L2993P (103 individuals) and Q3016R (152PKD1 haplotypes were produced with the microsatel-
individuals), but no other examples of either of theselites KG8, SM6, 16AC2.5, CW2, W5.2, SM7, and
transitions were observed on normal or affected chro-VK5AC (Harris et al. 1991; Aksentijevich et al. 1993;
mosomes.Peral et al. 1994; Snarey et al. 1994).
An abnormal digestion pattern was identiﬁed in the
Mut 4 product from OX1097 (P161). Direct sequencingResults
showed a 10739CrG transversion resulting in L3510V.
This change abolished restriction sites for HgaI andTo screen for mutations within the duplicated area of
PKD1, we developed an anchored RT-PCR approach. Cac81, and segregation to the patient’s three affected
offspring was demonstrated. Analysis of 192 further af-One unique primer (AH3 B2) situated within the single-
copy area (exon 34; ﬁg. 1) was employed to amplify fected and normal chromosomes showed no other exam-
ples of this change.PKD1-speciﬁc products extending Ç2 kb into the dupli-
cated region. The PKD1 speciﬁcity of these products Polymorphisms.—By use of NIRCA, a number of
other substitutions were detected, which were character-was tested by use of somatic-cell hybrids containing just
PKD1 or just the HG loci (for details, see Subjects and ized by direct sequencing and which, in population stud-
ies, were shown to be polymorphisms; these include aMethods). Mutations were screened in the single-copy
region and in the speciﬁcally ampliﬁed duplicated area substitution of two nucleotides, 9406GT/CC, resulting
in F/L3066 (ﬁg. 2b), which was found in 23.5% of theof PKD1 by two different methods—NIRCA and PTT.
NIRCA detects mismatches between in vitro–tran- individuals analyzed, including one homozygote. A tran-
sition 9541T/C, conserving P3110, was detected in 31%scribed RNAmolecules of£Ç1 kb, whereas PTT identi-
ﬁes mutations that alter the size of an in vitro–translated of individuals assayed, whereas the substitution 9880G/
A, conserving T3223, was found once. The polymor-product. These studies identiﬁed 11 PKD1 mutations,
which are summarized in ﬁgure 1 (details are given in phism 10737C/T, changing threonine to methionine (T/
M3509; ﬁg. 2a) created a SfaNI site and was foundtable 3).
in 2/192 of the individuals screened (1 of these 2 was
Mutations Identiﬁed by NIRCA affected). A 10743C/T change resulting in A/V3511 was
found in 14/150 individuals. Two further polymor-cDNA from 64 patients (including 24 in whom no
mutation had been detected in a previous, SSCP screen phisms were identiﬁed in the cDNA of different patients
during sequencing for mutations in exon 46. The ﬁrst,of exons 36–46; Peral et al. 1996b) was analyzed for
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Table 3
Mutations Identiﬁed in PKD1 Gene
Effect on
Name Pedigreea Nucleotide Change Coding Sequence Location Reference(s)
Nonsense:
E3020X P130 9269GrT GlurStop at 3020 EX25b Present paper
Q3513X P187 10748CrT GlnrStop at 3513 EX35 Present paper
Y3818X P117c 11665CrA TyrrStop at 3818 EX41 Peral et al. (1996a)
Q3837X P198 11720CrT GlnrStop at 3837 EX41 Peral et al. (1996b)
R4020X 4137T 12269CrT ArgrStop at 4020 EX44 Rossetti et al. (1996)
Q4041X VR4001 12332CrT GlnrStop at 4041 EX44 Turco et al. (1995); Torra
et al. (in press)
C4086X 1608 12469TrA CysrStop at 4086 EX45 Neophytou et al. (1996)
R4227X P89 12890CrT ArgrStop at 4227 EX46 Peral et al. (1996b); present
paper
Insertion/deletions:
8657delC P179 Deletion of C at 8657 Frameshifting after 2815 EX23b Present paper
9299delC P11 Deletion of C at 9299 Frameshifting after 3029 EX25b Present paper
10262del 2 kb P98 (OX114)c Deletion of 2 kb, IVS30–IVS34 Frameshifting after 3350 IVS30b–IVS34 European Polycystic Kidney
Disease Consortium (1994)
10708del 5.5 kb P95 (OX875) Deletion of 5.5 kb, IVS34–3 UTR Deletion of 3491–4302 IVS34–EX46 European Polycystic Kidney
Disease Consortium (1994)
10947insT P100 Insertion of T after 10947 Frameshifting after 3578 EX36 Peral et al. (1996b)
11457del15 P35 Deletion of 15 bp, 11457–11471 Deletion of 3749–3753 EX39 Peral et al. (1996b)
12739delA P225 Deletion of A at 12739 Frameshifting after 4176 EX46 Present paper
Splicing:
IVS31/25del19 P229c 19-bp deletion at 10378/25 Frameshifting after 3389 IVS31b Present paper
IVS39/1GrC P109 GrC at 11477/1 Frameshifting after 3717 IVS39 Present paper
IVS39/266del72 P167 Deletion of 72 bp, IVS39–EX40 Deletion of 3756–3772 IVS39–EX40 Peral et al. (1996b)
IVS43/17del18 S6046 18-bp deletion at 12211/17 Complex splicing IVS43 Peral et al. (1995)
IVS43/14del20 P138 20-bp deletion at 12211/14 Complex splicing IVS43 Peral et al. (1995)
IVS44/1GrC P4 (OX32) GrC at 12346/1 Deletion of 4001–4045 IVS44 European Polycystic Kidney
Disease Consortium (1994)
Missense:
L2993P P193 9189TrC LeurPro at 2993 EX25b Present paper
Q3016R P157 9258ArG GlnrArg at 3016 EX25b Present paper
L3510Vd P161 10739CrG LeurVal at 3510 EX35 Present paper
E3631Dd P125 11104GrC GlurAsp at 3631 EX36 Peral et al. (1996b)
a In which mutation was ﬁrst described.
b Mutation within the duplicated part of PKD1.
c De novo mutation occurs within the family.
d Conservative substitution that segregates with the disease and was not found in normal subjects.
12777C/T, changed serine to phenylalanine (S/F4189) showed that the mutation in OX46 was a deletion of a
C nucleotide from a run of three C’s (8657delC; ﬁg. 3b).and also was detected in the normal parent. The second
This generated a frameshift mutation that introduced 58was 12838T/C, conserving P4209.
novel amino acids before premature termination. This
Mutations Identiﬁed by PTT mutation destroyed an ApaI restriction site, which was
A large number of polymorphisms were identiﬁed by employed to conﬁrm the mutation and to show segrega-
NIRCA (see above), and signiﬁcant effort was required tion to the affected daughter. In the second patient,
to characterize these nonpathogenic changes. To over- OX61 (P11), direct sequencing revealed deletion of a C
come this problem, we employed PTT, which identiﬁes nucleotide (9299delC). This frameshift mutation intro-
aberrantly sized translation products and, hence, detects duced 43 novel amino acids after position 3029. De-
only disease-related mutations. We screened the entire struction of a CvJiI restriction site was used to conﬁrm
region from exons 22–46 in four different, overlapping the mutation and to trace the change in the family (for
segments, by PTT (ﬁg. 1 and table 2) in 101 unrelated details, see ﬁg. 3c and Subjects and Methods).
ADPKD patients; these included 61 patients analyzed Nonsense mutation in the duplicated area (P130).—
by NIRCA, plus 40 new families. Analysis of exons 22–27 by use of primers PTT 1,
Frameshifting mutations in the duplicated area (P179 showed a shorter peptide in patient OX973 (P130) (ﬁg.
and P11).—PTT analysis with the PTT 1 primers re- 3a), and direct sequencing revealed a 9269GrT substi-
vealed truncated polypeptides in two patients, OX46 tution changing Glu to a stop codon (E3020X) (ﬁg. 3d).
This change created an AluI restriction site, which was(P179) and OX61 (P11) (ﬁg. 3a). Direct sequencing
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tions in a 12-bp direct repeat within the intron (ﬁg. 4c),
and the deleted intron was 71 bp. The aberrant splicing
resulted in inclusion of the deleted intron, causing a 71-
bp frameshifting insertion in the cDNA, which intro-
duced 29 novel amino acids after position 3389, before
premature termination (ﬁg. 4c). This intronic deletion
and resulting aberrant splicing was similar to that else-
where described in two PKD1 patients with mutations in
intron 43 (Peral et al. 1995). In all these cases, defective
splicing probably resulted because the deleted intron
was too small to be processed efﬁciently (Wieringa et
al. 1984). Genomic DNA of a brother and sister of
OX1056 was available for study, and analysis showedFigure 2 NIRCA analysis. a, 3% Agarose gel resolving NIRCA
products generated with the Mut 4 primers. N Å normal control; P that neither sibling had the genomic deletion. Somatic
Å PKD1 patient (no mutation detected); and M Å HaeIII-digested cell–hybrid analysis indicated that the haplotype associ-
fX174 marker. Two abnormal digestion patterns (arrowheads). ated with the deleted chromosome also was present on
These digestion patterns were revealed, after the sequence was deter-
the chromosome of the unaffected brother, demonstra-mined, to be 10748CrT, giving rise to Q3513X in OX40 and to
ting that this was a de novo mutation (ﬁg. 4d).the polymorphism 10737C/T resulting in T/M3509 in an unaffected
individual. b, NIRCA analysis with the primers Mut 1, showing two
different abnormal digestion patterns (arrowheads), corresponding to Mutation Detected by Direct Analysis of an RT-PCR
9189TrC (L2993P) in OX1055 and to the polymorphism 9406GT/ Product: Skipping of Exon 39 (P109)
CC (F/L3066) in two other individuals. c, Direct sequencing of the
An RT-PCR product, Ç120 bp smaller than normal,nonsense mutation in OX40 (P187), showing the CrT transition at
was generated with the 1 Long primers (table 1) in pa-position 10748.
tient OX980 (P109). Direct sequencing showed a frame-
shifting deletion of 113 bp that was due to skipping
used to conﬁrm the mutation in genomic DNA and to of exon 39. Electrophoretic analysis of genomic DNA
show that it also was inherited by his affected daughter. showed no abnormal fragment, but sequencing demon-
Deletion of an A nucleotide in OX18 (P225).—A strated a GrC substitution at /1 of the splice-donor
shorter polypeptide in OX18 (ﬁg. 3e) was shown to be site following exon 39. This mutation, IVS39/1GrC,
due to a deletion of an A nucleotide at position 12739 created a DdeI site, which was used to conﬁrm the muta-
(12739delA). This frameshifting mutation resulted in tion and to show that it also was present in the only
the addition of 19 novel amino acids before premature other available affected individual. This frameshifting
termination, leaving a protein 107 amino acids shorter change introduced 58 novel amino acids, from position
than normal. This mutation was conﬁrmed by use of a 3717 of polycystin.
mismatch primer (see Subjects and Methods).
Nonsense mutation in P3.—A shorter PTT product in Discussion
OX21 (ﬁg. 3e) was revealed to be due to 12890CrT,
converting Arg4227 to a stop codon (R4227X). This We have described the ﬁrst examples of base-pair mu-
tations within the duplicated area of the PKD1 gene,mutation previously had been detected in another PKD1
family (P89), by SSCP (Peral et al. 1996b). By use of a the likely location of most mutations at this locus. These
have been identiﬁed and characterized by use of a novelmutation-speciﬁc primer pair (see Subjects and Meth-
ods), the nonsense mutation was conﬁrmed in three af- anchored RT-PCR strategy to generate PKD1-speciﬁc
products extendingÇ2 kb into the reiterated region. Thefected members of P3 and also in the three PKD1 pa-
tients from P89. development of such strategies is central to screening the
entire PKD1 gene for mutations, and the anchored RT-Inclusion of intron 31 (P229).—PTT analysis of
OX1056 by use of the PTT 2 primers showed a shorter PCR approach will allow the analysis of at least Ç4 kb
of the duplicated part of the gene. Other methods, suchpolypeptide, and analysis with primers ﬂanking the pre-
dicted position of the mutation revealed a larger frag- as exploiting the rare differences between the HG and
PKD1 sequences, will, however, be required in order toment in the cDNA (ﬁg. 4a). Sequencing showed that this
was due to the insertion of intron 31 into the cDNA. analyze the 5 region of PKD1.
PKD1-speciﬁc products have been assayed, for muta-Ampliﬁcation of OX1056 genomic DNA by use of prim-
ers ﬂanking the intron showed a smaller fragment (ﬁg. tion, by two different methods, NIRCA and PTT, which
previously had not been employed in analysis of this4b), and sequencing revealed an intronic deletion of 19
bp (IVS31/25del19), which did not affect either the 5 gene. An RT-PCR approach has been used so that larger
fragments can be screened without inclusion of intronicor 3 splice sites or the branch-point sequence (ﬁg. 4c).
The ends of the deletion lay within corresponding posi- DNA; PTT requires that the reading frame be preserved.
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Figure 3 PTT analysis. a, SDS-PAGE (17%) analysis of PTT products, with use of the PTT 1 primers. Arrowheads indicate truncated
polypeptides generated from mutant alleles in OX46 (P179), OX61 (P11), and OX973 (P130). P Å PKD1 patient (no mutation detected); N
Å normal control; and M Å C14-labeled Rainbow molecular-weight marker (Amersham). b and d, Direct sequencing of two PKD1 mutations
found by PTT (as shown in a): deletion of a C nucleotide (8657delC), visualized as doublets in the sequencing gel 3 to the deletion in OX46
(b) and the nonsense mutation 9269GrT (E3020X) in OX973 (d). c, Agarose gel showing ampliﬁed genomic DNA from 11 members of P11
whose DNA was digested with CvJiI. Affected individuals with the mutation 9299delC have lost a CvJiI site and therefore show the larger,
94-bp fragment (for details, see Subjects and Methods). e, Analysis of PTT products in a 15% SDS-PAGE with the primers PTT 4. Arrowheads
indicate truncated polypeptides generated from mutant alleles in OX21 (P3; R4227X) and OX18 (P225; 12739delA).
cDNA has been generated from lymphoblast cell lines, ﬁrst-pass method for mutation screening in PKD1;
ú80% of the mutations described so far would be de-but expression in blood leukocytes is sufﬁcient for
cDNA synthesis directly from a peripheral blood sam- tected by this method. Clearly, other approaches would
be required for the detection of missense mutations, andple. One potential disadvantage of the RT-PCR ap-
proach is that mutations eliminating expression from a second screen of those samples in which no PTT aber-
ration had been detected could employ NIRCA.the aberrant allele would not be detected. However, pre-
vious studies have shown expression from all mutated The advantage of generating PKD1-speciﬁc products
was that confusion between bona ﬁde mutations in thePKD1 alleles tested (European Polycystic Kidney Dis-
ease Consortium 1994; Peral et al. 1996b). Both NIRCA duplicated part of PKD1 and polymorphic changes at
the HG loci was avoided. The mutations detected inand PTT allow the analysis of larger fragments than
does SSCP (which is limited to Ç200 bp), with NIRCA this study were mainly frameshifting or stop mutations,
eliminating signiﬁcant portions of the gene and, hence,accurately detecting fragments £Ç1 kb and with PTT
accurately detecting fragments ú2 kb. The advantage clearly were pathogenic changes. In all cases (9 of 11)
in which samples were available, segregation of the mu-of PTT is that only changes that alter the size of the
translated product are identiﬁed—and hence most will tation with the disease has been demonstrated. It was
more difﬁcult, however, to determine whether the threebe pathogenic mutations. This is particularly important
in the case of PKD1, in which a high polymorphism:mu- detected substitutions were pathogenic mutations, espe-
cially since it presently is impossible to screen the entiretation ratio has been found by methods designed to de-
tect all mismatches (see discussion of results from PKD1 gene to exclude other changes. Clearly, the
changes must segregate with the disease and must notNIRCA). RT-PCR/PTT could prove to be an efﬁcient
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Figure 4 Splicing mutation in IVS31. a, RT-PCR products ampliﬁed with use of primers ﬂanking the position of the mutation (Mut 4F
and AH3B2), from a normal individual (N) and from patient OX1056 (P229). In addition to the normal fragment of 362 bp, a novel, larger
fragment of 433 bp is detected in OX1056 b, Ampliﬁed genomic DNA from OX1056 and a normal control, which reveals a smaller fragment
of 184 bp (normal size 203 bp) in the patient. c, Diagram of sequence of IVS31 (numbered 1–90), ﬂanked by exons 31 and 32 (blackened
region) and showing the amino acid sequence. The position of the 19-bp genomic deletion in OX1056 (P229) is shown, with the breakpoints
in corresponding positions of a 12-bp direct repeat in the intron (boldface). In the P229 cDNA the deleted intron is included, and 29 novel
amino acids (in boldface below the sequence) are introduced before premature termination, which is denoted by an asterisk. The gray-shaded
codon is an alternative splice variant in the PKD1 transcript (Harris et al. 1995). d, PKD1 haplotype analysis of P229 (for details, see Subjects
and Methods), showing that the haplotype found on the deleted chromosome (D; gray shaded) also is found in the normal brother without
the deletion (N), implying that this is a de novo change.
be found in a sizable screen of normal individuals. Even cerned (authors’ unpublished observation). If we look
at the residues in the REJ protein that correspond tothese criteria, however, will not exclude all rare poly-
morphisms. The L3510V change, for instance, passed those which are mutated, we can see that Leu2993 is
a very similar aliphatic residue, isoleucine (REJ 1329),the segregation and population tests, but the conserva-
tive nature of the change still makes it likely that it is a suggesting that mutation to proline may be signiﬁcant.
Similar analysis shows that the amino acid correspond-polymorphism. In contrast, the L2993P and Q3016R
changes are much less conservative. The introduction of ing to polycystin Gln3016 is asparagine (REJ 1357), a
very conservative substitution, indicating that the intro-proline can affect the secondary structure of the mole-
cule, which may disrupt a helixes or b stands. Likewise, duction of a charged residue may be important. Ulti-
mately, a functional test for polycystin, in which mis-the substitution of the neutral residue glutamine for a
positively charged arginine may be signiﬁcant. Compari- sense changes can be assayed, will be required to
determine whether they are mutations.son of these residues to PKD1 sequence from other spe-
cies (once they become available) will show whether All of the mutations so far described in typical PKD1
patients are summarized in table 3. In this limited datathese are highly conserved residues. Both changes are in
a part of polycystin in which no homology with other set, no clear hot spot for mutation is apparent, although
some clustering is observed. Four changes have beenproteins originally had been identiﬁed (Hughes et al.
1995; International Polycystic Kidney Disease Consor- described in the 253 bp of exon 25, whereas no muta-
tions have been detected in the 965 bp of exons 26–31.tium 1995). However, a region of homology with a sea
urchin receptor protein for egg jelly (REJ), which is pres- In a region of 12 bp (nt 10737–10748) in exon 35, one
mutation, a missense change, and two polymorphismsent on sea urchin sperm and is important in the acro-
some reaction, recently has been found in polycystin were identiﬁed. Several mutations also have been de-
scribed in exons 43 and 44, but this may be because(Moy et al. 1996). Although the region of described
homology does not cover the two missense mutations, primers to amplify this region were described at an early
stage (European Polycystic Kidney Disease Consortiumextention of the homology over this region can be dis-
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1994). The most striking feature is the variety of differ- renal cysts detected in infancy also were analyzed in this
study. However, these children had no clinical symptomsent mutations, with only two mutations—R4227 (Peral
et al. 1996b) and Q4041X (Turco et al. 1995; Torra of PKD1, and their ultrasound results probably were no
more severe than is typical for PKD1 in childhood.Overall,et al., in press)—described more than once. Although
Q4041X was found in three families, their geographical as previous studies have indicated (Peral et al. 1996a,
1996b), no clear correlation between the severity of renaland PKD1-haplotype differences indicated that the mu-
tation had recurred, rather than that the families were disease and the type or position of mutation was obvious.
Previous studies have not resolved whether PKD1mu-ancestrally related (Torra et al., in press). The present
study describes the third case of a de novo PKD1 muta- tations are inactivating or whether they generate a pro-
tein with a dominant negative or gain-of-function effect.tion (P229) (also see European Polycystic Kidney Dis-
ease Consortium 1994; Peral et al. 1996a), and one As frameshifting or stop mutations are identiﬁed further
5 in the gene (as in this study), the possibility that theother pedigree (P193) had a clearly negative family his-
tory. All of these ﬁndings illustrate both the problem mutations are inactivating seems more likely. Further-
more, recent evidence of loss of heterozygosity (althoughthat PKD1 poses for genetic diagnosis and that new
mutation at PKD1 is occurring at a signiﬁcant rate. at a low level) in cystic epithelia in ADPKD has sug-
gested a two-hit mechanism of disease, with inactivatingThe sequence similarity of PKD1 and the HG loci
raises the possibility that mutation in the duplicated part germ-line and somatic mutations (Qian et al. 1996; Bra-
sier and Henske 1997). The limited available analysisof PKD1 sometimes may be due to gene-conversion
events inserting deleterious mutations from the HG loci. of PKD2 mutations (Mochizuki et al. 1996; Peters et
al. 1996) also shows frameshifting and stop mutationsExamples of gene conversion being a major cause of
mutation have been described. Most mutations of 21- throughout the gene, indicating that PKD2 mutations
probably are inactivating.hydroxylase deﬁciency are due to gene-conversion or
deletion events involving recombination between the ste- An area of similarity between part of the transmem-
brane regions of polycystin and the PKD2 protein sug-roid 21-hydroxylase gene (CYP21) and a pseudogene
with 98% sequence similarity, which are separated by gests that they may have related roles (Mochizuki et al.
1996). Since polycystin is much larger (ú41) than the30 kb (White et al. 1994). Clearly, in the case of PKD1
and the HG loci, the separation is much greater (Ç15 PKD2 protein, however, the unique extracellular por-
tion of polycystin may have additional functions. It isMb), since they lie in different chromosome bands (i.e.,
16p13.3 in the case of PKD1 and 16p13.1 in the case possible that some of these may be mediated by alterna-
tively spliced or cleaved products. Recent evidence ofof HG). In a limited analysis of available HG cDNA
sequence, most of the described changes within the du- possible alternative splicing in the mouse, resulting in
the production of proteins terminating after exon 12,plicated area of PKD1 were not found at the HG locus.
Interestingly, however, the rarer nucleotide (T) found at has been described (Lo¨hning et al., in press). The severe
polycystic kidney disease associated with the TSC2/one frequent PKD1 polymorphism (9541C/T) was
found in the two different HG cDNAs analyzed. It is not PKD1 contiguous-gene syndrome may be due to simul-
taneous mutation of both the TSC2 gene and the PKD1clear whether this represents a gene-conversion event, a
polymorphism present before the original duplication, gene. Alternatively, if some products (such as truncated
N terminal proteins) are generated from the PKD1 geneor the same change occurring independently.
An important question that mutation detection will an- in typical PKD1 patients—but not in PKD1/TSC2 pa-
tients, who have null mutations at this locus—these mayswer in the case of PKD1 is whether there is a genotype/
phenotype correlation. Both the limited number of affected explain the differences, in disease presentation, between
the two disorders. Ultimately, for determination of themembers in many of the families studied and the localiza-
tion of mutations to only part of the gene mean, however, mutational mechanism in PKD1, it will be essential to
screen the whole gene for changes. This study has madethat this study provides only further anecdotal evidence.
Many of the probands experienced ESRD onset close to important progress toward that aim, with both speciﬁc
ampliﬁcation of the duplicated part of PKD1 and thethe age described as average for PKD1 (i.e., seven had
ESRD onset at age 50–57 years), although their mutations ﬁrst description of mutations from that region.
ranged from stop mutations, either in the middle of the
gene or close to the 3 end of the gene, tomissense changes.
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